Trial Profile

Expanded Access With Trappsol Cyclo for an Individual Patient With Late Onset Alzheimer's Disease

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydroxypropyl betadex (Primary)
Indications Alzheimer's disease
Focus Expanded access; Therapeutic Use
Sponsors CTD Holdings; Cyclo Therapeutics

Most Recent Events

20 May 2021 According to a Cyclo Therapeutics media release, based on data from this trial the company is planning an early phase clinical trial using Trappsol Cyclo intravenously in Alzheimer's Disease.
17 Jun 2020 18 months results presented in the Cyclo Therapeutics Media Release.
13 Aug 2019 Results presented in a CTD Holdings media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com